Mucosal Melanoma of the Oral Cavity: Understanding Your Pathology Report

Section Editor: Jason Wasserman MD PhD FRCPC
July 24, 2026

Mucosal melanoma of the oral cavity is a rare cancer that starts from melanocytes, the cells that produce the brown pigment called melanin. Small numbers of melanocytes are normally present in the epithelium, the thin surface lining of the mouth. When these cells become malignant and grow into a tumor, the result is mucosal melanoma. In the mouth, it arises most often on the upper gums (maxillary gingiva) and the hard palate, although it can develop anywhere on the lining of the mouth.

Mucosal melanoma accounts for well under 1% of all melanomas and is far less common than melanoma of the skin. It differs from cutaneous (skin) melanoma in three important ways: it is not caused by sun exposure, it carries a different set of genetic changes, and it is staged using a separate system. It tends to be found at a later point in its course than skin melanoma, largely because it develops out of sight inside the mouth, and it has a stronger tendency to spread to lymph nodes and distant organs.

This article will help you understand the findings in your pathology report, what each term means, and why it matters for your care.

What causes mucosal melanoma of the oral cavity?

The cause of mucosal melanoma of the oral cavity, a cancer that begins in the pigment-producing melanocytes lining the mouth, is not well understood. Unlike melanoma of the skin, it has no established link to ultraviolet light, and this is the clearest difference between the two diseases. Sun protection does not prevent it, and having had a lot of sun exposure does not cause it.

There is also no proven link to tobacco, alcohol, denture irritation, or the other exposures associated with squamous cell carcinoma, the far more common cancer of the mouth. Some tumors appear to arise within an area of long-standing pigmentation in the mouth called oral melanosis, and a proportion of patients report a pigmented patch that was present for months or years before the diagnosis. Many tumors, however, develop with no identifiable precursor lesion at all.

What is understood is what happens inside the cells. Melanocytes acquire genetic changes that switch on the signaling pathways controlling growth and survival, so the cells keep dividing when they should stop. The specific genes involved are different from those in skin melanoma. Changes in SF3B1, NF1, KIT, and NRAS are relatively common, while BRAF changes, which drive roughly 40% of skin melanomas, are found in fewer than 10% of mucosal melanomas. These differences are the reason mucosal melanoma responds differently to some drugs, and they are described further in the biomarker section below. Mucosal melanoma is not an inherited condition, and having it does not mean your relatives are at increased risk.

What are the symptoms of mucosal melanoma of the oral cavity?

Mucosal melanoma of the oral cavity often causes no pain in its early stages, and because it develops inside the mouth, it is frequently noticed first by a dentist during a routine examination rather than by the patient. When symptoms do occur, the most common are:

A brown, blue-black, or unevenly pigmented patch, flat plaque, or raised lump in the mouth, most often on the upper gums or the hard palate
A pigmented area that has changed in size, shape, or color, or that has developed more than one color
A pink or flesh-colored lump with no visible pigment at all. Roughly one in five oral mucosal melanomas is amelanotic, meaning it produces no visible pigment, and these are easily mistaken for something harmless
An ulcer or sore that bleeds or will not heal
Swelling, loosening of teeth, or dentures that no longer fit
Pain, numbness, or altered sensation, usually a later development
A lump in the neck from spread to a lymph node

Most pigmented spots in the mouth are harmless. An oral melanotic macule, an amalgam tattoo from old dental work, and normal racial pigmentation are all far more common than melanoma. What raises concern is a pigmented area that is new, growing, changing, irregular in outline or color, or that bleeds or ulcerates.

How is the diagnosis made?

The diagnosis of mucosal melanoma of the oral cavity is made when tissue is removed and examined under the microscope by a pathologist. The tissue is obtained by biopsy of the suspicious area. Because pigmented lesions in the mouth are usually harmless, the biopsy is often performed to rule out melanoma, and the diagnosis can come as a complete surprise.

Under the microscope, the pathologist looks for markedly abnormal cells growing beneath the surface lining. The cells of mucosal melanoma vary greatly in appearance, which is one reason this diagnosis can be difficult. They may be epithelioid (large and rounded), spindle-shaped (long and thin), plasmacytoid, or so abnormal that they resemble no normal cell at all, and several of these appearances often occur in the same tumor. The cells may grow in sheets, in nests, or in interlacing bundles. Melanin pigment may be abundant, scanty, or entirely absent. Additional clues include abnormal melanocytes scattered upward through the surface lining (pagetoid spread) or lined up along its base (lentiginous growth), numerous and often abnormal mitotic figures, and necrosis.

Because the appearance is so variable, a group of tests called immunohistochemistry is almost always used to confirm the diagnosis, especially when the tumor produces no visible pigment. These tests are described in the next section. They also separate melanoma from other cancers that can look similar in the mouth, including poorly differentiated squamous cell carcinoma, lymphoma, and sarcoma.

The initial biopsy establishes the diagnosis but samples only part of the tumor. Thickness, margin status, and involvement of bone or deep soft tissue can only be assessed accurately once the whole tumor has been removed, so the report on the surgical resection contains considerably more information. Once melanoma is confirmed, imaging is performed to determine how far the disease extends. This normally means a contrast-enhanced CT scan or MRI of the mouth, jaws, and neck, along with imaging of the chest, abdomen, and often the brain, because mucosal melanoma spreads to distant organs more readily than most cancers of the mouth. PET-CT is frequently used for this purpose.

Immunohistochemistry

Immunohistochemistry uses antibodies to detect specific proteins inside the tumor cells. For melanoma, it is the main way the pathologist confirms the diagnosis, and it is especially important when the tumor makes no visible pigment. The results appear on your pathology report as a list of markers, each reported as positive (the protein is present) or negative (it is absent). No single marker is relied on by itself, so a panel is used together. The markers most often reported for mucosal melanoma are:

S100: positive. Present in almost all melanomas. It is a very sensitive marker, meaning melanoma rarely fails to show it, which makes a negative result useful for arguing against melanoma.
SOX10: positive. Another highly reliable marker of melanoma. Like S100, it stays positive even in the spindle cell and desmoplastic types that can otherwise be hard to recognize.
HMB-45: positive. More specific to melanoma, meaning a positive result points strongly to melanoma rather than another tumor. It may be patchy or negative in the spindle cell and desmoplastic types.
Melan-A (also called MART-1): positive. Another melanoma-specific marker, often used alongside HMB-45. It too can be weak or absent in spindle cell and desmoplastic tumors.
MITF and tyrosinase: positive. Additional melanoma markers that may be included to help confirm the diagnosis.

Your report may list only some of these, and the exact pattern depends on the type of melanoma. Tumors made of rounded (epithelioid) cells usually stain strongly, while spindle cell and desmoplastic tumors may show only S100 and SOX10. A pathologist reads the whole panel together rather than relying on any single result.

Types of mucosal melanoma of the oral cavity

Mucosal melanoma of the oral cavity is divided into a small number of types based on how the tumor grows under the microscope. Naming a type does not mean a different disease was found; it describes the growth pattern the pathologist saw. Many tumors show more than one pattern, and some reports do not assign a type at all.

Mucosal lentiginous melanoma. Abnormal melanocytes spread out along the base of the surface lining before invading downward. This is the pattern most often seen in the mouth. It may be preceded by a visible pigmented patch present for some time.
Nodular melanoma. The tumor forms a compact mass and grows downward early, with little or no spread along the surface. Tumors of this type are often thick by the time they are found.
Desmoplastic melanoma. A rare type made up mostly of spindle cells set in dense desmoplastic (scar-like) tissue. It usually lacks visible pigment, frequently shows perineural invasion, and often requires extensive immunohistochemistry to diagnose because it can closely resemble a benign scar or a spindle cell tumor.
Mixed and unclassified patterns. Many oral mucosal melanomas combine features of more than one type, and the report may simply describe the growth pattern rather than assign a name.

Is mucosal melanoma given a histologic grade?

No. Unlike most cancers, mucosal melanoma of the oral cavity is not assigned a histologic grade. There is no recommended grading system for this tumor, and the staging manual states this explicitly. If you are looking for a grade on your report and cannot find one, nothing has been omitted.

The reason is that grading systems work by measuring how far tumor cells have drifted from the normal cell they came from, and this distinction does not usefully separate mucosal melanomas into groups with different outcomes. Essentially all of them behave as high-grade cancers. Instead of a grade, the features that carry prognostic weight in this disease are tumor thickness, ulceration, mitotic rate, perineural and lymphovascular invasion, involvement of bone or deep soft tissue, margin status, and whether lymph nodes contain tumor. Each of these is described in its own section below.

Tumor thickness and depth of invasion

Tumor thickness measures how far a mucosal melanoma of the oral cavity extends from the surface of the mouth down to its deepest point, reported in millimeters. Some reports call this depth of invasion. Your report may also give the greatest surface dimension of the tumor in millimeters or centimeters.

The role of this measurement is different from its role in skin melanoma, and this difference causes confusion. In melanoma of the skin, thickness (the Breslow depth) is the single most important factor determining the T category and drives most treatment decisions. In mucosal melanoma of the head and neck, thickness is not used to assign the T category at all. The staging system classifies every mucosal melanoma confined to the lining and the tissue immediately beneath it as pT3, regardless of how thick or how wide it is. Only growth into deeper structures raises the category further.

Thickness is still recorded, and it still carries information. Thicker tumors, and in several published series those greater than 5 mm, are associated with a higher risk of spread and worse survival. It is best understood as a prognostic measurement rather than a staging measurement. Because the lining of the mouth is thin and sits directly on bone in places such as the hard palate and the gums, even a modestly thick tumor may reach bone, which is why thickness and bone involvement are reported separately.

Ulceration, necrosis, and mitotic rate

Alongside the tumor thickness, a pathology report on mucosal melanoma of the oral cavity describes several microscopic features that help predict how the tumor is likely to behave. These appear as short statements on the report and are easy to overlook, but each one carries meaning.

Ulceration. The surface lining over the tumor has broken down, leaving the tumor exposed. Ulceration is common in oral mucosal melanoma and is associated with worse survival. Your report will state whether it is present or absent.
Necrosis. Areas of dead tumor tissue within the tumor itself, usually because the tumor has outgrown its blood supply. Its presence is associated with more advanced disease.
Mitotic rate. A count of how many tumor cells are dividing, expressed as the number of mitotic figures per square millimeter of tumor. A higher count means faster growth and is associated with a higher risk of spread.
Tumor-infiltrating lymphocytes. Immune cells found within the tumor, a sign that the immune system has recognized it. When reported, their presence is generally regarded as a favorable feature.
Pigmentation. Whether the tumor contains visible melanin. Tumors with no visible pigment (amelanotic) are more often diagnosed late and are associated with a higher rate of recurrence.

Tumor extension into nearby structures

Because mucosal melanoma of the oral cavity arises on a thin lining that sits close to bone, muscle, and other structures, a key question for the pathologist and surgeon is whether the tumor has grown beyond the lining and the soft tissue immediately beneath it. In this disease, the answer directly determines the T category, since thickness and size do not.

Confined to the lining and immediately underlying soft tissue. The tumor has not reached deeper structures. This corresponds to pT3, the lowest category in this staging system.
Deep soft tissue, cartilage, bone, or overlying skin. The tumor has grown into the jawbone (maxilla or mandible), into cartilage, into deeper muscle and soft tissue, or through to the skin of the face. This corresponds to pT4a, described in the staging system as moderately advanced disease. Bone involvement is relatively common in tumors of the hard palate and gums.
Brain, dura, skull base, lower cranial nerves, masticator space, carotid artery, prevertebral space, or mediastinal structures. These represent the most extensive local growth and correspond to pT4b, described as very advanced disease. Tumors in this category usually cannot be removed completely by surgery.

Perineural invasion

Perineural invasion means that cells from a mucosal melanoma of the oral cavity are growing along, around, or within the sheath surrounding a nerve. Nerves run throughout the gums, palate, cheeks, and tongue, carrying signals for sensation and movement, and they provide a pathway along which tumor cells can travel well beyond the visible edge of the tumor.

Perineural invasion is common in mucosal melanoma and is particularly characteristic of the desmoplastic type. The pathologist identifies it when tumor cells are seen surrounding a nerve or growing within the layers of tissue around it. Your report will state whether it is present or absent, and may note the size of the nerve involved. When present, it indicates a higher risk that the tumor will return at the original site, and it is one of the findings the treatment team weighs when considering radiation after surgery.

Lymphovascular invasion

Lymphovascular invasion means that cells from a mucosal melanoma of the oral cavity have entered a small blood vessel or a lymphatic channel near the tumor. Lymphatic channels are thin-walled vessels that drain fluid toward the lymph nodes; blood vessels carry blood throughout the body. Both offer a route by which tumor cells can leave the mouth.

The pathologist recognizes this when tumor cells are seen sitting inside a vessel rather than in the surrounding tissue. Your report will state whether it is present or absent. Lymphovascular invasion has been identified in published studies as one of the stronger independent predictors of outcome in mucosal melanoma of the head and neck, because this cancer spreads through the bloodstream to distant organs more readily than most cancers arising in the mouth.

Surgical margins

Margins are the cut edges of tissue removed during an operation for mucosal melanoma of the oral cavity. The pathologist inks the outer surfaces of the specimen, cuts it into thin slices, and examines under the microscope how close the tumor comes to each edge.

Negative (clear) margin. No tumor cells at the inked edge. This suggests the tumor was completely removed. Achieving negative margins is associated with better survival, and it is one of the few factors in this disease that surgery can directly influence.
Close margin. Tumor cells come near the edge without reaching it. The distance is reported in millimeters, and its significance is judged alongside the location and the surgical options available.
Positive (involved) margin. Tumor reaches the inked edge, meaning tumor may remain. This is associated with worse survival and is a common reason for further surgery or for radiation to the tumor bed.

Two points are specific to melanoma in the mouth. First, the anatomy makes wide margins difficult. On the hard palate and gums there is very little tissue between the lining and the bone, so the surgeon may have limited room even when the tumor is small, and bone is sometimes removed to obtain an adequate deep margin. Second, the report may describe melanoma in situ or abnormal melanocytes at a mucosal margin separately from invasive tumor at a margin. This finding reflects the tendency of this tumor to extend along the surface lining beyond what is visible, and it is one reason margins are checked carefully and frozen sections may be used during the operation. Frozen section results are preliminary; the final assessment in your report is based on the complete specimen.

Lymph nodes

Lymph nodes are small immune organs that filter fluid draining from the tissues. In the neck they are arranged in numbered levels on each side. Mucosal melanoma of the oral cavity can spread to these nodes, most often to levels I through III, the levels closest to the mouth.

Lymph nodes may be removed as part of a neck dissection at the time of surgery, or a single suspicious node may be sampled. Sentinel lymph node biopsy, standard practice for melanoma of the skin, is used far less often for mucosal melanoma of the mouth and its value here is not established. Your report will describe:

The number of lymph nodes examined and the number containing melanoma. Usually written as a ratio, such as 1 of 22.
The levels involved. Which regions of the neck contained positive nodes.
The size of the largest deposit. Measured in millimeters.
Extranodal extension. Whether tumor cells have broken through the outer capsule of a node into the surrounding tissue. This is an adverse finding associated with a higher risk of recurrence.

The staging system for mucosal melanoma is unusually simple on this point. It does not count the number of involved nodes or measure their size; it records only whether regional lymph node spread is present or absent. Even so, the details above are reported because they inform treatment planning and because the number of involved nodes carries prognostic information beyond what the stage captures. Finding no melanoma in any lymph node is a favorable result, though this cancer can still spread through the bloodstream without involving lymph nodes first, which is why imaging of the rest of the body is part of the workup regardless.

Biomarker and molecular testing

Biomarkers are measurable features of a tumor, such as a change in a gene or a protein on the tumor cell surface, that help predict how the cancer may respond to particular drugs. In mucosal melanoma of the oral cavity, biomarker testing is not needed to make the diagnosis and does not change the approach to surgery. It becomes important when systemic drug treatment is being planned, which in this disease is common because of the high risk of spread. Testing is usually performed by next-generation sequencing, a method that examines many genes at once from a single tissue sample.

The most important thing to understand is that mucosal melanoma carries a different set of genetic changes from melanoma of the skin. Results from skin melanoma do not transfer directly, and a patient reading general melanoma information may find that the biomarkers emphasized there are the ones least likely to be found here.

BRAF

BRAF is a gene that makes a protein relaying growth signals along a pathway called the MAPK pathway. A mutation at a specific spot in the gene, most often called V600E or V600K, locks the protein in the “on” position so the signal never stops. In melanoma of the skin, roughly 40% of tumors carry a BRAF V600 mutation. In mucosal melanoma, the figure is under 10%, so most patients with this diagnosis will have a negative result.

BRAF V600 mutation detected. Indicates eligibility for combined BRAF and MEK inhibitor therapy, such as dabrafenib (Tafinlar) with trametinib (Mekinist) or encorafenib (Braftovi) with binimetinib (Mektovi). These drugs block the overactive pathway directly and often produce a rapid response.
No BRAF mutation detected (BRAF wild type). The most common result in mucosal melanoma. BRAF-targeted drugs would not be expected to work, and treatment planning centers on immunotherapy and on the other genes below.

Further detail is available in the site’s article on BRAF mutations in melanoma.

KIT

KIT is a gene that produces a receptor protein on the cell surface controlling growth and survival. Mutations and extra copies of this gene are considerably more common in mucosal melanoma than in melanoma of the skin, occurring in roughly 15 to 20% of cases, and this is one of the clearest biological differences between the two diseases. When altered, the receptor sends continuous growth signals even without an external trigger.

KIT mutation detected. The report will usually name the specific change and which part of the gene (the exon) it sits in, because only some changes respond to treatment. Mutations in exon 11 and exon 13 are the most likely to respond to KIT inhibitor drugs such as imatinib (Gleevec) or nilotinib (Tasigna). This result may open the option of targeted therapy or of a clinical trial.
No KIT mutation detected. KIT-directed drugs would not be expected to help, and other options are considered.

Further detail is available in the site’s article on KIT mutations in melanoma.

NRAS

NRAS sits on the same growth-signaling pathway as BRAF, one step upstream of it. Mutations are found in roughly 10 to 20% of mucosal melanomas. No drug directly targeting mutated NRAS is approved, so this result does not currently open a specific treatment, but it matters for two reasons. It carries prognostic weight, having been identified in published studies as an independent predictor of shorter survival in mucosal melanoma. It also identifies eligibility for clinical trials, including trials of MEK inhibitors that act further along the same pathway.

NRAS mutation detected. Associated with a less favorable outlook and may identify clinical trial options.
No NRAS mutation detected. A normal result for this gene.

Other genetic changes reported on sequencing

Sequencing panels examine many genes at once and frequently report changes for which no approved drug currently exists. In mucosal melanoma the ones most often seen are SF3B1 (found in roughly 15% of cases and largely specific to mucosal melanoma), NF1 (roughly 14%), and, in head and neck tumors particularly, PDGFRA and ROS1. Changes in TERT, TP53, and GNAQ or GNA11 may also appear. These findings do not usually change standard treatment today, but they help confirm that the tumor is a mucosal rather than a cutaneous melanoma and they may identify clinical trials. More on how these panels work is available in the overview of next-generation sequencing in cancer.

PD-L1

PD-L1 is a protein displayed on the surface of some tumor cells and nearby immune cells. It acts as a brake on the immune system: when it attaches to its partner protein on a T cell, the T cell is told to stand down. Immunotherapy drugs called checkpoint inhibitors release this brake. PD-L1 is measured by immunohistochemistry and reported either as the percentage of tumor cells that stain or as a combined score, depending on the laboratory.

It is worth being clear about how much weight this result carries. In melanoma, unlike in several other cancers, PD-L1 is not used as a gatekeeper for immunotherapy. Its ability to predict response has proven limited, and checkpoint inhibitors are offered to patients with advanced melanoma regardless of the result. A PD-L1 result of 0% does not mean immunotherapy is unavailable. The result does contribute by helping the medical oncology team choose between checkpoint inhibitor combinations, since some regimens have shown greater benefit in tumors with low PD-L1 expression. Further detail is available in the site’s article on PD-L1 and tumor mutational burden in melanoma.

Tumor mutational burden

Tumor mutational burden (TMB) counts how many mutations a tumor carries, expressed as mutations per megabase (mut/Mb) of DNA examined. Tumors carrying many mutations produce more abnormal proteins and are easier for the immune system to recognize. Skin melanomas caused by ultraviolet damage typically have among the highest counts of any cancer. Mucosal melanomas, which are not caused by ultraviolet light, generally have much lower counts, and this is one proposed explanation for their somewhat lower response rates to immunotherapy.

TMB of 10 mut/Mb or greater (TMB-high). Indicates eligibility for pembrolizumab (Keytruda) in previously treated cancers that have spread, an approval that applies regardless of where the cancer started. This result is uncommon in mucosal melanoma.
TMB less than 10 mut/Mb. Below that threshold. This is the usual result in mucosal melanoma and does not rule out benefit from immunotherapy, which is offered on other grounds.

More information about the tests described here is available in the site’s Biomarkers and Molecular Testing section.

Pathologic stage (pTNM)

The pathologic stage of a mucosal melanoma of the oral cavity describes how far the cancer has spread, based on examination of the tissue removed at surgery. It uses the TNM system, combining T for the primary tumor, N for regional lymph nodes, and M for metastasis to distant organs. The letter “p,” as in pT and pN, means the category was determined by examining tissue under the microscope. Mucosal melanoma of the head and neck has its own chapter in the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual, separate from both skin melanoma and the other cancers of the mouth. The M category is determined by imaging rather than by pathology.

Two features of this system surprise most patients and are worth understanding before reading the categories. First, there is no pT1 or pT2 category. Every mucosal melanoma starts at pT3, no matter how small or thin it is, because the disease as a whole carries a high risk of spread. A pT3 tumor is the least advanced category available, not an advanced one. Second, and for the same reason, the lowest overall stage is stage III. There is no stage I or stage II mucosal melanoma. A patient told they have stage III disease has the earliest stage this system recognizes, which is a very different situation from stage III in most other cancers. Melanoma in situ of the mucosa is so rare that it is excluded from the system altogether.

Tumor stage (pT)

pT3. Tumor limited to the lining of the mouth and the soft tissue immediately beneath it, regardless of how thick the tumor is or how wide it measures.
pT4a. Moderately advanced disease. Tumor involves deep soft tissue, cartilage, bone, or the overlying skin.
pT4b. Very advanced disease. Tumor involves the brain, the dura (the covering of the brain), the skull base, the lower cranial nerves (IX, X, XI, or XII), the masticator space, the carotid artery, the prevertebral space, or structures in the chest.

Nodal stage (pN)

pNX. Regional lymph nodes cannot be assessed, usually because none were removed.
pN0. No melanoma found in any lymph node examined.
pN1. Melanoma present in one or more regional lymph nodes. Unlike most staging systems, this one does not subdivide by the number or size of involved nodes.

Stage groups

Stage III. pT3, no lymph node involvement, no distant spread. The earliest stage in this system.
Stage IVA. pT4a with no lymph node involvement; or pT3 or pT4a with lymph node involvement. No distant spread.
Stage IVB. pT4b, with or without lymph node involvement, and no distant spread.
Stage IVC. Melanoma has spread to distant parts of the body, whatever the T and N categories.

What is the prognosis for mucosal melanoma of the oral cavity?

Prognosis means the likely course and outcome of a disease. Mucosal melanoma of the oral cavity is a serious cancer with outcomes considerably poorer than those of melanoma of the skin, and the honest picture is worth stating plainly rather than softening. Published five-year overall survival figures for mucosal melanoma of the head and neck vary widely between studies, generally falling between roughly 20% and 40%, with the variation reflecting small series, differing stage mixes, and treatment eras.

Stage is the strongest determinant, and stage-specific figures are more informative than an overall average. In one of the larger published series of head and neck mucosal melanoma, five-year overall survival was approximately 67% for stage III, 24% for stage IVA, and 8% for stage IVB. These are averages drawn from patients treated over several decades. They describe groups, not individuals, and importantly, they largely predate the routine use of modern immunotherapy, which has changed outcomes in advanced melanoma substantially and continues to evolve.

The specific findings on the pathology report associated with worse outcomes are:

Higher stage. The single strongest factor, driven by growth into bone and deep tissue and by lymph node involvement.
Positive surgical margins. Associated with worse survival. Re-excision to achieve negative margins appears to recover much of that disadvantage.
Lymphovascular invasion. Identified as one of the stronger independent predictors of outcome in this disease.
Tumor thickness greater than 5 mm. Associated with higher rates of spread, even though thickness does not affect the stage.
Ulceration. Associated with worse overall survival.
High mitotic rate. Reflects faster growth and a higher risk of distant spread.
Absence of visible pigment (amelanotic tumor). Associated with higher recurrence rates, in part because these tumors are recognized later.
NRAS mutation. An independent predictor of shorter survival in published series.
Lymph node involvement. Indicates a higher risk of distant spread.

The most important pattern to understand is that most patients who do poorly do so because the melanoma has spread to distant organs, not because it returned in the mouth. Local control with surgery is often achieved and still followed by distant spread, which is why systemic treatment and whole-body imaging are central to care in this disease and why follow-up continues long term.

What happens after the diagnosis?

Once mucosal melanoma of the oral cavity has been confirmed by pathology, the report is reviewed together with imaging and your overall health, normally at a multidisciplinary tumor board involving head and neck surgery, medical oncology, radiation oncology, radiology, and pathology. Because this cancer is rare, referral to a center with specific experience in melanoma and head and neck cancer is common and often worth asking about.

For disease that has not spread to distant organs, complete surgical removal with negative margins is the mainstay of treatment, and margin status on the pathology report is the finding that most directly reflects whether that goal was met. The anatomy of the mouth often limits how wide a margin can be taken, and reconstruction may be needed when bone or a large area of tissue is removed. Radiation after surgery is frequently considered, particularly when margins are positive or close, when perineural invasion is present, or when lymph nodes are involved. Radiation improves control of the disease at the original site, although it has not been shown to extend overall survival, and the team will weigh that trade-off with you.

Systemic treatment plays a larger role here than in most mouth cancers, because of the high risk of distant spread. Immune checkpoint inhibitors are the foundation. For advanced or metastatic disease, the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) is generally the preferred first option in mucosal melanoma, having produced response rates of roughly 40% in this group, compared with roughly 30% for anti-PD-1 treatment alone. Checkpoint inhibitors after surgery are also considered for patients at high risk of recurrence. If the report shows a BRAF V600 mutation, combined BRAF and MEK inhibitor therapy becomes an option; if it shows a treatment-responsive KIT mutation, a KIT inhibitor may be considered. Because approved options remain limited in this rare cancer, clinical trials are an important part of the discussion, and molecular results from the report often determine which trials are open to you.

Follow-up involves regular examination of the mouth and neck together with imaging of the rest of the body, since distant spread is the most common pattern of failure. Supportive care runs alongside treatment and includes dental assessment before radiation, nutrition support, speech and swallowing therapy, and help with any prosthesis needed after removal of part of the palate or jaw.

Questions to ask your doctor

Where exactly in my mouth did the melanoma start, and how large was it?
What was the tumor thickness, and was ulceration present?
Did the melanoma grow into bone, deep soft tissue, or skin?
Was perineural invasion or lymphovascular invasion found?
Were the surgical margins negative, and if not, is further surgery being considered?
Was melanoma in situ found at any margin?
How many lymph nodes were removed, and did any contain melanoma?
What are my pT and pN categories, and what is my overall stage?
My report says stage III. Since there is no stage I or stage II for this cancer, what does stage III mean in my situation?
Was molecular testing performed, and were BRAF, KIT, or NRAS changes found?
Do my molecular results open any targeted therapy or clinical trial options?
Is immunotherapy being considered, and would it be given before or after surgery?
Is radiation to the area being considered, and what would it be expected to achieve?
What imaging will be done to check whether the melanoma has spread elsewhere, and how often?
Should I be seen at a center that specializes in melanoma or head and neck cancer?